| Electrical Equipment Industry | Industrials Sector | Mr. Chung-Yue Pao CEO | TWSE Exchange | TW0003058004 ISIN |
| TW Country | - Employees | 3 Aug 2021 Last Dividend | 2 Feb 2024 Last Split | - IPO Date |
Formosa Laboratories, Inc., founded in 1985 and headquartered in Taoyuan, Taiwan, is a significant player in the pharmaceutical industry with a global reach, including countries like India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, and Canada. The company specializes in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers. Its operations are broad, encompassing not only the production of these critical components but also engaging in chemical trading and investment activities. Formosa Laboratories, Inc. aims to deliver high-quality products across various therapeutic areas through its extensive range of services and a commitment to innovation and excellence.
Formosa Laboratories, Inc. manufactures APIs for a variety of purposes, including anticancer treatments, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filters, treatments for iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and many more areas. These ingredients are fundamental in the formulation of effective and safe pharmaceuticals.
The company produces injectable formulations in several therapeutic areas including IDA, MRI agents, oncology, and others. These injectables are developed using rigorous standards to ensure patient safety and therapeutic efficacy.
Formosa offers a suite of contract services including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization. Additionally, it provides injectable manufacturing along with secondary packaging, labeling, and serialization services, reflecting its capacity to cater to the comprehensive needs of pharmaceutical companies.
The company's custom fermentation services demonstrate its capabilities in utilizing microorganisms for the production of pharmaceutical products, a critical component of biotechnological manufacturing.
Formosa Laboratories, Inc. offers peptide synthesis services, showcasing its expertise in creating specific and complex molecules that are pivotal in the development of novel therapeutics.
This service range includes antibody development and manufacture, peptide and polymer drug conjugation, Linker-payload design, synthesis, and manufacturing, bio-conjugation and purification, cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture, and regulatory support. These services underline the company’s capabilities in the cutting-edge field of antibody-drug conjugates, which represent a significant advancement in targeted cancer therapies.